3rd Swiss Autoimmune Liver Disease Meeting 2020
March 13th-14th 2020
Università della Svizzera Italiana, Auditorium
Lugano, Switzerland

Course Organisers:

Andreas Cerny, Switzerland,
Pietro Invernizzi, Italy
Giorgina Mieli-Vergani, UK
Benedetta Terzioli Beretta-Piccoli, Switzerland
Federica Sallusto, Switzerland
Diego Vergani, UK

Contacts
Fondazione Epatocentro Ticino, Lugano
www.swissautoimmuneliver.ch
swissaildmeeting@epatocentro.ch
+41 91 960 8503

Credits
SSP Société Suisse de Pediatrie: 11 credits
SGAIM: the meeting is allowed to be accredited for "formazione allargata SGAIM"
European CME credits (ECMEC®s): 10 credits, each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
SSAI Swiss Society for Allergology and Immunology: 11 credits
SSG SSG Schweizerische Gesellschaft für Gastroenterologie: 13 march: 6 credits; 14 march: 5 credits
SGPath SSPath Schweizerische Gesellschaft für Pathologie: 13 march: 6 credits; 14 march: 5 credit

ENDORSEMENTS
SCIENTIFIC PROGRAMME

March 13th

10:30 – 11:00 Arrivals and welcome coffee

11:00 – 11:10 Welcome and introduction
Andreas Cerny, Switzerland
Benedetta Terzioli Beretta-Piccoli, Switzerland

11:10 – 11:20 Welcome
Mario Bianchetti, founding Dean of the Master Medical School, Switzerland

Basic science session 1
Chairs: Andreas Cerny, Switzerland
       Federica Sallusto, Switzerland

11:20 – 11:40 Genetics in primary biliary cholangitis beyond GWAS
Pietro Invernizzi, Italy

11:40 – 11:50 Discussion

11:50 – 12:10 Preventing the progression of PBC
Eric Gershwin, USA

12:10 – 12:20 Discussion

12:20 – 12:40 Effector and regulatory T-cells in autoimmune diseases
Federica Sallusto, Switzerland

12:40 – 12:50 Discussion

12:50 – 14:00 Lunch & Poster viewing

Basic science session 2
Chairs: Michael Manns, Germany
       Pietro Majno-Hurst, Switzerland

14:00 – 14:20 The impact of gut microbiome on T-cell trafficking
Giandomenica Iezzi, Switzerland

14:20 – 14:30 Discussion

14:30 – 14:50 Novel approaches to autoantibody characterization
Antonio Lanzavecchia, Switzerland

14:50 – 15:00 Discussion

15:00 – 15:20 Immunometabolic drugs
Michael Trauner, Austria

15:20 – 15:30 Discussion
15:30 – 15:50  Living in the Liver: overcoming constraints on T cells
Mala Maini, UK
15:50 – 16:00  Discussion

16:00 – 16:20  Coffee break & Poster viewing

16:20 – 16:40  Anti-tumor autologous T-cell therapy for HBV-associated hepatocellular carcinoma
Antonio Bertoletti, Singapore
16:40 – 16:50  Discussion

16:50 – 17:10  Animal model of autoimmune liver diseases
Urs Christen, Germany
17:10 – 17:20  Discussion

17:20 – 17:40  Gut-liver axis
Antonio Moschetta, Italy
17:40 – 17:50  Discussion

17:50 – 18:30  3 oral presentations selected among submitted abstract
18:30 – 18:40  What have we learned and what should we do next
Pietro Invernizzi, Italy

March 14th

Clinical session 1
Chairs: Andrea De Gottardi, Switzerland
       Maria Isabel Lucena, Switzerland

08:30 – 08:50  Bile duct lesions in autoimmune hepatitis and interface hepatitis in primary biliary cholangitis
Alberto Quaglia, UK
08:50 – 09:00  Discussion

09:00 – 09:20  Autoimmune hepatitis type 2
Giorgina Mieli-Vergani, UK
09:20 – 09:30  Discussion

09:30 – 09:50  Imaging in sclerosing cholangitis
Tom Hemming Karlsen, Norway
09:50 – 10:00  Discussion

10:00 – 10:20  Coffee break & Poster viewing

10:20 – 10:40  There is more than one cause for primary sclerosing cholangitis
Richard Thompson, UK
10:40 – 10:50  Discussion
Autoantibodies in autoimmune liver diseases: clinical aspects
Luigi Muratori, Italy

Beyond guidelines
Michael Manns, Germany

Lunch & Poster viewing

Clinical session 2
Chairs: Eric Gershwin, USA
Florian Bihl, Switzerland

Drug-induced liver injury and autoimmunity
Raúl Andrade, Spain

Post-transplant autoimmune liver diseases
Diego Vergani, UK

3 oral presentations selected among submitted abstract

What have we learned and what should we do next
Eric Gershwin, USA

Concluding remarks
Andreas Cerny, Benedetta Terzioli Beretta-Piccoli